ABBVIE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 167.8 USD | -1.01% |
|
+2.16% | +8.28% |
| 12:11pm | Scholz promises support for pharma sector in Germany as Merck invests | RE |
| Apr. 23 | US CDC warns of harmful reactions to fake Botox injections | RE |
ETFs positioned on AbbVie Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.12% | 6 M€ | 0.00% | - | |
| 6.85% | 18 M€ | +3.04% | - | |
| 6.26% | 13 M€ | -.--% | ||
| 4.81% | 2 M€ | -25.75% | ||
| 3.32% | 9 M€ | -.--% | - | |
| 3.10% | 2 M€ | -.--% | - | |
| 2.93% | 1 M€ | +16.32% | ||
| 2.69% | 5 M€ | -72.95% | - | |
| 2.51% | 1 M€ | +2.21% | - | |
| 2.35% | 1,026 M€ | +6.20% | - | |
| 2.06% | 2 M€ | +5.19% | ||
| 1.89% | 16 M€ | -3.37% | ||
| 1.80% | 26 M€ | +16.85% | - | |
| 1.63% | 8 M€ | -.--% | ||
| 1.62% | 9 M€ | -4.31% | - | |
| 1.61% | 4 M€ | -.--% | - | |
| 1.61% | 3 M€ | +15.16% | - | |
| 1.61% | 13 M€ | -.--% | - |
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
167.8
USD
Average target price
184.1
USD
Spread / Average Target
+9.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.28% | 297B | |
| +22.99% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +12.41% | 219B | |
| +6.50% | 199B | |
| -9.86% | 196B | |
| -8.75% | 149B | |
| -5.21% | 146B | |
| +1.20% | 117B |
- Stock Market
- Equities
- ABBV Stock
- Funds and ETFs AbbVie Inc.
